STXS
Price
$2.19
Change
-$0.14 (-6.01%)
Updated
Jan 30 closing price
Capitalization
204.38M
26 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$12.47
Change
+$0.20 (+1.63%)
Updated
Jan 30 closing price
Capitalization
2.49B
25 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

STXS vs XRAY

Header iconSTXS vs XRAY Comparison
Open Charts STXS vs XRAYBanner chart's image
Stereotaxis
Price$2.19
Change-$0.14 (-6.01%)
Volume$841.71K
Capitalization204.38M
DENTSPLY SIRONA
Price$12.47
Change+$0.20 (+1.63%)
Volume$3.43M
Capitalization2.49B
STXS vs XRAY Comparison Chart in %
STXS
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
STXS vs. XRAY commentary
Feb 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STXS is a Buy and XRAY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 01, 2026
Stock price -- (STXS: $2.19 vs. XRAY: $12.47)
Brand notoriety: STXS and XRAY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: STXS: 168% vs. XRAY: 92%
Market capitalization -- STXS: $204.38M vs. XRAY: $2.49B
STXS [@Pharmaceuticals: Other] is valued at $204.38M. XRAY’s [@Pharmaceuticals: Other] market capitalization is $2.49B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $178.74B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.52B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STXS’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • STXS’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, XRAY is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STXS’s TA Score shows that 6 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).

  • STXS’s TA Score: 6 bullish, 5 bearish.
  • XRAY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, STXS is a better buy in the short-term than XRAY.

Price Growth

STXS (@Pharmaceuticals: Other) experienced а -17.98% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -2.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.17%. For the same industry, the average monthly price growth was +1.50%, and the average quarterly price growth was +26.40%.

Reported Earning Dates

STXS is expected to report earnings on Feb 27, 2026.

XRAY is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-2.17% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XRAY($2.49B) has a higher market cap than STXS($204M). XRAY YTD gains are higher at: 9.099 vs. STXS (-4.783). STXS has higher annual earnings (EBITDA): -22.57M vs. XRAY (-433M). XRAY has more cash in the bank: 1.27B vs. STXS (10.5M). STXS has less debt than XRAY: STXS (5.58M) vs XRAY (2.48B). XRAY has higher revenues than STXS: XRAY (3.62B) vs STXS (30.1M).
STXSXRAYSTXS / XRAY
Capitalization204M2.49B8%
EBITDA-22.57M-433M5%
Gain YTD-4.7839.099-53%
P/E RatioN/AN/A-
Revenue30.1M3.62B1%
Total Cash10.5M1.27B1%
Total Debt5.58M2.48B0%
FUNDAMENTALS RATINGS
STXS vs XRAY: Fundamental Ratings
STXS
XRAY
OUTLOOK RATING
1..100
9212
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
7860
P/E GROWTH RATING
1..100
5886
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for STXS (99). This means that XRAY’s stock grew significantly faster than STXS’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STXS (100). This means that XRAY’s stock grew similarly to STXS’s over the last 12 months.

XRAY's SMR Rating (97) in the Medical Specialties industry is in the same range as STXS (100). This means that XRAY’s stock grew similarly to STXS’s over the last 12 months.

XRAY's Price Growth Rating (60) in the Medical Specialties industry is in the same range as STXS (78). This means that XRAY’s stock grew similarly to STXS’s over the last 12 months.

STXS's P/E Growth Rating (58) in the Medical Specialties industry is in the same range as XRAY (86). This means that STXS’s stock grew similarly to XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STXSXRAY
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
58%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 11 days ago
55%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 4 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
73%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
51%
View a ticker or compare two or three
Interact to see
Advertisement
STXS
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NFPDF20.501.92
+10.36%
Nissin Food Products
IACYF9.88N/A
N/A
Inter Action Corp. Yokohama
SNCPF54.30N/A
N/A
Sun Corp.
MLYNF2.78N/A
N/A
Malayan Banking Berhad
BBBMF0.19-0.02
-7.39%
LUX METALS CORP

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-6.01%
SMTI - STXS
44%
Loosely correlated
+4.46%
TWST - STXS
36%
Loosely correlated
-1.23%
CERS - STXS
35%
Loosely correlated
+0.43%
NVST - STXS
35%
Loosely correlated
+0.34%
XRAY - STXS
34%
Loosely correlated
+1.63%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been closely correlated with NVST. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+1.63%
NVST - XRAY
67%
Closely correlated
+0.34%
AZTA - XRAY
57%
Loosely correlated
-0.31%
TFX - XRAY
56%
Loosely correlated
-1.05%
SOLV - XRAY
53%
Loosely correlated
+0.59%
ALGN - XRAY
53%
Loosely correlated
-0.66%
More